Catalent Inc

Chart & Performance

D1W1MN

P/E

—

P/S

2.63

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

4.40%

Rev. gr., 5y

11.71%

Revenues

4.38b

+2.46%

Net income

-1.04b

L+349.57%

CFO

268m

+2.68%

Earnings

Feb 07, 2025

Profile

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

URL

https://www.catalent.com/

IPO date

Jul 31, 2014

Employees

17,800

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2024‑06	2023‑06	2022‑06	2021‑06	2020‑06	2019‑06	2018‑06	2017‑06	2016‑06	2015‑06
Income
Revenues	4,381,000 2.46%	4,276,000 -11.43%	4,828,000 20.76%
Cost of revenue	3,428,000	3,234,000	3,211,000
Unusual Expense (Income)
NOPBT	953,000	1,042,000	1,617,000
NOPBT Margin	21.75%	24.37%	33.49%
Operating Taxes	16,000	(83,000)	86,000
Tax Rate	1.68%		5.32%
NOPAT	937,000	1,125,000	1,531,000
Net income	(1,043,000) 349.57%	(232,000) -146.49%	499,000 -14.70%
Dividends			(4,000)
Dividend yield			0.02%
Proceeds from repurchase of equity	9,000	4,000	352,000
BB yield	-0.09%	-0.05%	-1.84%
Debt
Debt current	61,000	547,000	31,000
Long-term debt	4,870,000	8,626,000	4,185,000
Deferred revenue		(76,000)	202,000
Other long-term liabilities	256,000	247,000	65,000
Net debt	4,595,000	12,967,000	3,645,000
Cash flow
Cash from operating activities	268,000	261,000	439,000
CAPEX	(327,000)	(583,000)	(660,000)
Cash from investing activities	(327,000)	(962,000)	(1,884,000)
Cash from financing activities	74,000	521,000	1,031,000
FCF	1,022,000	(125,000)	976,000
Balance
Cash	289,000	280,000	538,000
Long term investments	47,000	(4,074,000)	33,000
Excess cash	116,950		329,600
Stockholders' equity	(1,183,000)	(66,000)	10,653,000
Invested Capital	9,961,000	9,789,000	8,884,400
ROIC	9.49%	12.05%	18.43%
ROCE	10.85%	10.63%	17.17%
EV
Common stock shares outstanding	181,000	181,000	178,000
Price	56.23 29.68%	43.36 -59.59%	107.29 -0.77%
Market cap	10,177,630 29.68%	7,848,160 -58.91%	19,097,620 3.90%
EV	14,772,630	20,839,160	33,249,620
EBITDA	1,442,000	1,464,000	1,995,000
EV/EBITDA	10.24	14.23	16.67
Interest	254,000	184,000	123,000
Interest/NOPBT	26.65%	17.66%	7.61%